title: Not all facial swellings are angioedemas!
authors.forename: M
authors.initials: M
authors.lastname: Fricker
authors.forename: P
authors.initials: P
authors.lastname: Dubach
authors.forename: A
authors.initials: A
authors.lastname: Helbling
authors.forename: E
authors.initials: E
authors.lastname: Diamantis
authors.forename: P M
authors.initials: PM
authors.lastname: Villiger
authors.forename: U
authors.initials: U
authors.lastname: Novak
mesh_terms: D000328:Adult; D000799:Angioedema / Q000175:diagnosis*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001706:Biopsy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003937:Diagnosis, Differential; D004317:Doxorubicin / Q000008:administration & dosage; D004487:Edema / Q000175:diagnosis / Q000209:etiology*; D005145:Face; D006258:Head and Neck Neoplasms / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D016399:Lymphoma, T-Cell / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D015434:Panniculitis / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D011237:Predictive Value of Tests; D011239:Prednisolone / Q000008:administration & dosage; D012307:Risk Factors; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone